The company
NovaBridge Biosciences - American Depositary Shares
NBP · Nasdaq
NBP stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 24.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 38
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $1.2M
- Insider sales, 12 months
- $309K
- Officials’ trades on record
- 0
- Institutions holding
- 48 (+3)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Phillip Andrew DennisChief Medical Officer | sold | 8,209at $0.71 | 18 Sep 2026filed 21 Sep 2026 |
| Sean Wuxiong CaoChief Bus. Development Officer | sold | 107,978at $0.74 | 9 Sep 2026filed 11 Sep 2026 |
| Cong Claire XuEVP, Clinical Development | sold | 3,282at $0.79 | 31 Aug 2026filed 1 Sep 2026 |
| Cong Claire XuSVP, Clinical Development | sold | 4,485at $0.89 | 6 Jul 2026filed 7 Jul 2026 |
| Phillip Andrew DennisChief Medical Officer | sold | 8,494at $0.66 | 18 Jun 2026filed 22 Jun 2026 |
| Cong Claire XuSVP, Clinical Development | sold | 3,494at $3.94 | 1 Jun 2026filed 2 Jun 2026 |
| Sean Wuxiong CaoDirector, Officer | sold | 21,399at $1.99 | 14 May 2026filed 18 May 2026 |
| Mark Arnold HaglerOfficer | bought | 230,000at $2.51 | 24 Apr 2026filed 28 Apr 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| HHLR ADVISORS, LTD.unchanged · filed 14 Aug 2026 | 5,980,568$11.7M | 00.0% |
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 3,653,228$7.1M | -184,970−4.8% |
| AIHC Capital Management Ltdadded · filed 13 Aug 2026 | 2,878,033$5.6M | +615,100+27.2% |
| Siren, L.L.C.reduced · filed 13 Aug 2026 | 2,004,739$3.9M | -995,261−33.2% |
| MARSHALL WACE, LLPnew · filed 13 Aug 2026 | 1,231,946$2.4M | +1,231,946 |
| Candriam S.C.A.unchanged · filed 13 Aug 2026 | 1,132,563$2.2M | 00.0% |
| ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026 | 1,000,000$1.9M | 00.0% |
| TWO SIGMA INVESTMENTS, LPnew · filed 14 Aug 2026 | 851,348$1.7M | +851,348 |
| RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026 | 758,226$1.5M | +485,814+178.3% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 686,208$1.3M | +58,712+9.4% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.